ADCC-enhanced CTLA-4 Antibody of ImmuneOnco Received Approval of NMPA for Clinical Trial

On November 4, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that IMM27M, the newly developed ADCC-enhanced CTLA-4 antibody was approved by NMPA for clinical trial research. This is another major milestone for ImmueOnco. ......

2021-11-05

The first patient in the Phase Ib trial of IMM01 successfully enrolled

October 27, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that IMM01, the drug candidate of a SIRPα-Fc fusion protein targeting human CD47, successfully moves into Phase Ib trial, the first dose was given to a f......

2021-10-26

ImmuneOnco won the "Top 20 Innovation and Entrepreneurship in Pudong New Area in 2020"

On the September 29, 2021, Pudong New Area held commendation event for "2021 Outstanding Economic Contribution Enterprises ". ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. won the Price of Top 20 of "2020 Pudong New Area Innovation and Entrepreneursh......

2021-09-29

ImmuneOnco sets up wholly-owned subsidiary—ImmuneOnco BioPharm (Shanghai) Co., Ltd.

On September 28, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") wholly-owned subsidiary-ImmuneOnco BioPharm (Shanghai) Co., Ltd. was established in Zhangjiang Science City (hereinafter ......

2021-09-28

ImmuneOnco：Clinical Research Application for IMM27M was accepted by the National Medical Products Administration (NMPA)

On September 1, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that clinical research application for newly developed IMM27M, an ADCC-enhanced CTLA-4 antibody, has been officially accepted by N......

2021-09-06